NCT02331303 is a clinical trial of Radium-223 dichloride (Xofigo, BAY88-8223) in Neoplasms, sponsored by Bayer.

Who is sponsoring NCT02331303?

NCT02331303 is sponsored by Bayer.

What drugs are being tested in NCT02331303?

Interventions in NCT02331303: Radium-223 dichloride (Xofigo, BAY88-8223).

Is NCT02331303 still recruiting?

NCT02331303 is currently completed. Last updated 23 January 2018.

Last reviewed 2018-01-23 · How we verify

NCT02331303

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Drug Utilization Study of Radium-223 in Sweden

Completed Last updated 23 January 2018

What this trial tests

trial testing Radium-223 dichloride (Xofigo, BAY88-8223) in Neoplasms in 37 participants. Completed in 19 December 2017.

Timeline

15 April 2015

Primary endpoint
19 December 2017

19 December 2017

Quick facts

Lead sponsor	Bayer
Status	Completed
Study type	OBSERVATIONAL
Enrollment	37
Start date	15 April 2015
Primary completion	19 December 2017
Estimated completion	19 December 2017
Sites	1 location across Sweden

Drugs / interventions tested

Radium-223 dichloride (Xofigo, BAY88-8223) — full drug profile →

Conditions studied

Neoplasms — all drugs for Neoplasms →

Sponsor

Bayer — full company profile →

Who can join

Eligibility, any sex, with Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to evaluate the extent of potential off-label use of Xofigo in Sweden.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
Nilsson S. · · 2016 · cited 27× · PMID 26779616 · DOI 10.1007/s11912-015-0495-4

Verify or expand the search:

Other trials of Radium-223 dichloride (Xofigo, BAY88-8223)

Trials testing the same drug.

NCT05301062 — A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Ad · terminated
NCT04521361 — A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones · Phase 1 · completed
NCT04597125 — RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhi · Phase 4 · active not recruiting
NCT04516161 — EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Sur · completed
NCT04232761 — Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, W · completed

Other recruiting trials for Neoplasms

Currently open trials in the same condition.

NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02331303 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 23 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02331303.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing